Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients

Journal of Thoracic Oncology

Volumn 10, Issue 10, 2015, Pages 1437-1443

  Marchetti, Antonio ^a   Palma, John F ^b   Felicioni, Lara ^a   De Pas, Tommaso M ^c   Chiari, Rita ^d   Del Grammastro, Maela ^a   Filice, Giampaolo ^a   Ludovini, Vienna ^e   Brandes, Alba A ^f   Chella, Antonio ^g   Malorgio, Francesco ^h   Guglielmi, Flavio ^a   De Tursi, Michele ⁱ   Santoro, Armando ^j   Crinò, Lucio ^j   Buttitta, Fiamma ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b ROCHE MOLECULAR SYSTEMS   (United States)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^e BELLARIA HOSPITAL   (Italy)

^f UNIVERSITY HOSPITAL OF PISA   (Italy)

^g Ospedale Civile di Pescara   (Italy)

^h Ospedale di Sulmona   (Italy)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^j UNIVERSITY OF PERUGIA   (Italy)

more..

Author keywords

EGFR mutations; Next generation sequencing; NSCLC; Plasma; Predictive medicine

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ALLELE; ARTICLE; ASSESSMENT OF HUMANS; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; COPY NUMBER VARIATION; DIAGNOSTIC TEST ACCURACY STUDY; DILUTION; EXON; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA; POINT MUTATION; POLYMERASE CHAIN REACTION SYSTEM; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; SEMIQUANTITATIVE INDEX; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR BIOPSY; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CASE CONTROL STUDY; ENZYMOLOGY; GENETIC SCREENING; GENETICS; LUNG NEOPLASMS; MUTATION; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CLINICAL TRIALS, PHASE II AS TOPIC; ERLOTINIB HYDROCHLORIDE; GENETIC TESTING; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84942521073     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000643     Document Type: Article

References (16)

1. Keedy VL, Temin S, Somerfeld MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering frst-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-2127.
2. Kerr KM, Bubendorf L, Edelman M, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014;25:1681-1690.
3. Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S; ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii27-iii39.
4. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med 2006;354:526-528; author reply 526-528.
5. Kim ES, Hirsh V, Mok T, et al. Geftinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818.
6. Mok TS, Wu YL, Thongprasert S, et al. Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
7. Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep 2014;4:6269.
8. Douillard J Y, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-1353.
9. Li X, Ren R, Ren S, et al. Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients. Transl Oncol 2014;7:341-348.
10. Vallée A, Marcq M, Bizieux A, et al. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer 2013;82:373-374.
11. Weber B, Meldgaard P, Hager H, et al. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specifc PCR assays. BMC Cancer 2014;14:294.
12. Zhao X, Han RB, Zhao J, et al. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration 2013;85:119-125.
13. Marchetti A, Del Grammastro M, Felicioni L, et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One 2014;9:e103883.
14. Marchetti A, Del Grammastro M, Filice G, et al. Complex mutations & sub-populations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. PLoS One 2012;7:e42164.
15. Buttitta F, Felicioni L, Del Grammastro M, et al. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fuids by next-generation sequencing. Clin Cancer Res 2013;19:691-698.
16. Thress K, Brant R, Carr H, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of technologies to support the clinical development of AZD9291. J Clin Oncol 2014;32:Abstr 8092.